Please login to the form below

Not currently logged in
Email:
Password:

Zynteglo

This page shows the latest Zynteglo news and features for those working in and with pharma, biotech and healthcare.

BMS scores EU okay for first-in-class anaemia drug Reblozyl

BMS scores EU okay for first-in-class anaemia drug Reblozyl

The beta thalassemia market could prove tougher to crack because bluebird bio’s newly approved gene therapy Zynteglo offers patients a cure in a single treatment.

Latest news

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics